Amicus Therapeutics, Inc.

Organisation

47 Hulfish Street, Princeton, NJ, United States, 08542

Headquarters

Employees

Health Technology

Industry

John Crowley

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Price

Target

Amicus Therapeutics, Inc. (FOLD) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Amicus Therapeutics, Inc. (FOLD) share price will touch around $14.5 in next 12-months.

Currently 17 wall-street analysts regularly analyze the financials of Amicus Therapeutics, Inc. on a frequent basis to provide recommendations along with target share price. 17 analysts offering 12-month price forecasts for Amicus Therapeutics, Inc. (FOLD) have a share price target of $14.5. This median of share price forecast represents a 0.9% upside from the latest price of $14.37 as on 18.03.26.

Amicus Therapeutics, Inc. (FOLD) Share Price Forecast

Home

US Stocks

Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics, Inc. Stock Forecast

Amicus Therapeutics, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Amicus Therapeutics, Inc. (FOLD): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Amicus Therapeutics, Inc.'s share price and its median forecast price. As on 18.03.26, the difference is -33.93%

Amicus Therapeutics, Inc. Forecast and Target Price

Amicus Therapeutics, Inc. (FOLD) Share Price Forecast

Amicus Therapeutics, Inc. (FOLD) Price vs Consensus Price Target

Amicus Therapeutics, Inc. (FOLD) Share Price Forecast v/s Share Price Today

Amicus Therapeutics, Inc. (FOLD): Difference between Current Price & Median Forecasted Price

Amicus Therapeutics, Inc. (FOLD) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price